KMT2A and acute myeloid leukemia: We established that the CD37 mRNA was overexpressed in a wide range of AML patients’ samples, especially in the adverse risk AML group, such as t(11q23)/MLL AML, indicating that this AML population could potentially benefit from a CAR therapy targeting CD37.